Genmab Reallocates Resources Away From Acasunlimab Program To Strengthen Portfolio Focus
Genmab A/S (GMAB) has made a strategic decision to halt ongoing clinical trials for acasunlimab, redirecting its research and development efforts toward high-impact candidates in its late-stage portfolio. The biotech firm will concentrate resources on priority initiatives including EPKINLY, petosemtamab, and rinatabart sesutecan, which the company believes offer greater therapeutic potential and commercial viability.
The reallocation reflects Genmab's refined capital allocation strategy and commitment to p
Genmab A/S (GMAB) has made a strategic decision to halt ongoing clinical trials for acasunlimab, redirecting its research and development efforts toward high-impact candidates in its late-stage portfolio. The biotech firm will concentrate resources on priority initiatives including EPKINLY, petosemtamab, and rinatabart sesutecan, which the company believes offer greater therapeutic potential and commercial viability.
The reallocation reflects Genmab's refined capital allocation strategy and commitment to p